News about Market

Merck Delivers Robust Q2 2026 Performance

Merck reported strong Q2 2026 results with 4.1 percent organic sales growth, higher EBITDA, upgraded full-year guidance and planned Bio-Techne acquisition.

Market | 06/08/2026 | By News Bureau

Evexta Bio, Roche Partner to Evaluate Novel Breast Cancer Combination Therapy

Evexta Bio has entered a clinical collaboration with Roche to evaluate its investigational therapy rupitasertib in combination with giredestrant for the treatment of advanced ER+, HER2-, ESR1-mutated breast cancer.

Market | 05/08/2026 | By News Bureau

Fermenta Biotech Debuts on NSE, Marking New Chapter in Its 75-Year Growth Journey

Fermenta Biotech celebrated its NSE listing with a ceremonial bell-ringing event, marking a significant milestone in its 75-year legacy and strengthening its presence across India's capital markets.

Market | 05/08/2026 | By News Bureau

Genprex Partners with Roche Diagnostics to Advance Biomarker Validation for Precision Lung Cancer Therapy

Genprex has partnered with Roche Diagnostics to validate TROP2 biomarkers for patient selection in non-small cell lung cancer trials, aiming to accelerate precision medicine and improve treatment outcomes.

Market | 04/08/2026 | By News Bureau

GSK India Reports 24 Percent PAT Growth in Q1 FY27

GSK India reported 15 percent revenue growth to INR 924 crore and a 24 percent rise in Q1 FY27 PAT to INR 253 crore, with EBITDA margin of 32 percent.

Market | 04/08/2026 | By News Bureau

Supernus and Indivior to Merge in All-Stock Deal to Create Diversified CNS Biopharma Leader

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction, creating a diversified CNS-focused biopharmaceutical company with 11 marketed therapies, projected annual revenue of USD 2.2 billion and expanded capabilities in psychiatry, neurology and addiction treatment.

Market | 04/08/2026 | By News Bureau

Biocon Announces US Commercial Launch of Yesafili, a Biosimilar to Regeneron's Eylea 2 mg

Biocon has launched Yesafili, an interchangeable biosimilar to Eylea 2 mg in the US, expanding access to treatment for Age-related Macular Degeneration (AMD) and other retinal diseases.

Market | 03/08/2026 | By News Bureau

US FDA Expands Approval of Novartis' Pluvicto for Earlier Treatment of Advanced Prostate Cancer

The US FDA has approved Novartis' Pluvicto for use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding access to the radioligand therapy at an earlier stage of disease.

Market | 03/08/2026 | By News Bureau

Sun Pharma Reports Q1FY27 Results

Sun Pharma reported a 10.1 percent YoY rise in Q1 FY27 sales to INR 151,836 million, while net profit increased to INR 28,948 million, driven by strong business growth.

Market | 01/08/2026 | By News Bureau |  125

Lupin Launches Generic Sugammadex Injection in the US Following FDA Approval

Lupin launches Sugammadex Injection in the United States after receiving US FDA approval for its Abbreviated New Drug Application. The bioequivalent version of Merck's Bridion Injection is indicated for reversing neuromuscular blockade in adult and paediatric patients aged two years and older undergoing surgery.

Market | 31/07/2026 | By News Bureau